Correvio Pharma Revenue Growth Rates (CORV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Correvio Pharma Corp   (CORV)
 

CORV's Revenue Growth by Quarter and Year

Correvio Pharma 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CORV Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December 32.63
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 32.63

CORVs Annual Revenue
Correvio Pharma 's Revenue in the fiscal year 2019 $ 32.63 millions
Correvio Pharma 's Revenue in the fiscal year 2018 $ 28.67 millions
Correvio Pharma 's Revenue in the fiscal year 2017 $ 24.01 millions
Correvio Pharma 's Revenue in the fiscal year 2016 $ 25.26 millions
Correvio Pharma 's Revenue in the fiscal year 2015 $ 20.91 millions




CORV Revenue fourth quarter 2019 Y/Y Growth Comment
Correvio Pharma Corp reported Revenue increase of 13.83% year on year in the fourth quarter 2019, to $ 32.63 millions, this is lower than Correvio Pharma Corp 's recent average Revenue increase of 16.62%.

Looking into fourth quarter 2019 results within Major Pharmaceutical Preparations industry 94 other companies have achieved higher Revenue growth. While Correvio Pharma Corp ' s Revenue growth of 13.83% ranks overall at the positon no. 1177 in the fourth quarter 2019.


CORV Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December 13.83 % 19.41 % 2939.24 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   13.83 % 19.41 % 2939.24 % -

Financial Statements
Correvio Pharma 's fourth quarter 2019 Revenue $ 32.63 millions CORV's Income Statement
Correvio Pharma 's fourth quarter 2018 Revenue $ 28.67 millions Quarterly CORV's Income Statement


CORV Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   13.83 % 19.41 % 2939.24 % -


Back to CORV Growth rate Comparisons >> Back to CORV Growth rate Comparisons >>


Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #95
Healthcare Sector #218
Overall #1177

Revenue Y/Y Growth Statistics
High Average Low
19.44 % 16.62 % 13.81 %
(Dec 31 2018)   (Dec 31 2019)
Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #95
Healthcare Sector #218
Overall #1177
Revenue Y/Y Growth Statistics
High Average Low
19.44 % 16.62 % 13.81 %
(Dec 31 2018)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Correvio Pharma 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CORV's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CORV's IV. Quarter Q/Q Revenue Comment


Correvio Pharma 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Dec 31 2017)		 12 Months Ending
(Dec 31 2016)		 12 Months Ending
(Dec 31 2015)
Cumulative Revenue 12 Months Ending $ 32.63 $ 28.67 $ 24.01 $ 25.26 $ 20.91
Y / Y Revenue Growth (TTM) 13.81 % 19.44 % -4.94 % 20.78 % -30.4 %
Year on Year Revenue Growth Overall Ranking # 21 # 0 # 0 # 0 # 21
Seqeuential Revenue Change (TTM) 13.81 % 19.44 % -4.94 % 20.78 % -30.4 %
Seq. Revenue Growth (TTM) Overall Ranking # 21 # 0 # 0 # 0 # 21


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2019 period, Correvio Pharma 's cumulative twelve months Revenue were $ 33 millions, company would post below average annual Revenue growth of -30.4% year on year, if the fiscal year would end at Dec 31 2019.
A slow-down in the Correvio Pharma 's Revenue growth from the 0% growth in Dec 31 2018.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 21.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 8
Overall # 21

Revenue TTM Y/Y Growth Statistics
High Average Low
2942.84 %
 992.03 %
13.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 8
S&P 500 # 21
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2019 period, Correvio Pharma 's cumulative twelve months Revenue were $ 33 millions, company would post below average annual Revenue growth of 13.81% year on year, if the fiscal year would end at Dec 31 2019.
A slow-down in the Correvio Pharma 's Revenue growth from the 0% growth in Dec 31 2018.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 21.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 8
Overall # 21

Revenue TTM Y/Y Growth Statistics
High Average Low
2942.84 %
992.03 %
13.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 8
S&P 500 # 21




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CORV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Dec 31 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2019
Strongbridge Biopharma plc24.19%$ 24.191 millions
Fortress Biotech Inc 23.79%$ 23.790 millions
Immucell Corporation23.67%$ 23.668 millions
Infusystem Holdings Inc23.61%$ 23.612 millions
Procyon Corporation23.32%$ 23.318 millions
Inspiremd Inc 23.24%$ 23.236 millions
Nanostring Technologies Inc 22.97%$ 22.972 millions
Tactile Systems Technology Inc 22.85%$ 22.854 millions
Adamas Pharmaceuticals Inc22.78%$ 22.779 millions
Alexion Pharmaceuticals Inc 22.63%$ 22.635 millions
Cytosorbents Corporation22.19%$ 22.192 millions
Jazz Pharmaceuticals Plc22.10%$ 22.097 millions
Intuitive Surgical Inc 22.09%$ 22.093 millions
Sientra Inc 22.02%$ 22.023 millions
Glaukos Corp21.77%$ 21.771 millions
Align Technology inc 21.68%$ 21.678 millions
Heron Therapeutics Inc 21.63%$ 21.630 millions
Utah Medical Products Inc21.28%$ 21.279 millions
Biocorrx Inc 20.85%$ 20.850 millions
Penumbra Inc20.26%$ 20.258 millions
Axogen inc 20.18%$ 20.181 millions
Edwards Lifesciences Corporation20.09%$ 20.088 millions
Medpace Holdings Inc 19.66%$ 19.661 millions
Neovasc Inc 19.60%$ 19.604 millions
Cellectis S a 19.32%$ 19.315 millions
Curis Inc 19.31%$ 19.310 millions
Cardiff Oncology Inc 18.67%$ 18.666 millions
Sarepta Therapeutics Inc 18.60%$ 18.596 millions
Integrated Biopharma Inc18.30%$ 18.298 millions
Quotient Limited18.12%$ 18.117 millions


About Correvio Pharma Revenue Growth Rates (CORV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.